TOP > 外国特許検索 > THERAPEUTIC AGENT FOR NONALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS

THERAPEUTIC AGENT FOR NONALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS UPDATE

外国特許コード F170009240
整理番号 (S2016-0536-N0)
掲載日 2017年9月21日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP009538
国際公開番号 WO 2017155053
国際出願日 平成29年3月9日(2017.3.9)
国際公開日 平成29年9月14日(2017.9.14)
優先権データ
  • 特願2016-046340 (2016.3.9) JP
発明の名称 (英語) THERAPEUTIC AGENT FOR NONALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS UPDATE
発明の概要(英語) The present invention provides a prophylactic and/or therapeutic agent for nonalcoholic fatty liver disease (NAFLD) and nonacoholic steatohepatitis (NASH) obtained by including lansoprazole. Lansoprazole has been used safely as a therapeutic agent for gastric ulcers and duodenal ulcers, and so may be a safe and useful drug for treating NAFLD and NASH as well.
従来技術、競合技術の概要(英語) BACKGROUND ART
In recent years, due to the change in life style due to the increase in obesity and insulin resistance, to consume alcohol even though fat accumulation, inflammation-associated necrosis, fibrosis such as liver tissue that indicates a non-alcoholic steatohepatitis (hereinafter sometimes abbreviated as' NASH '.) Which the patient has been reported (non-patent document 1). Fatty liver is not impaired who exhibit unexplained chronic progressive liver disease is nonalcoholic fatty liver disease (hereinafter sometimes abbreviated as' NAFLD '.) Collectively referred to as, cirrhosis of the liver lesions to which the activity of the high and the switching of the liver disease is associated with the highest frequency and results in cell death defined NASH (2014 clinical guidelines NAFLD/NASH Society Japan; or less, in the present specification, typically NASH and NAFLD stands for indicating all of the, 'NAFLD/NASH' used at all.). As the main feature of the clinical conditions of NAFLD/NASH, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activity and the like increase. Cirrhosis and liver cancer patient NASH such as increased risk to develop into a fatal disease, prevention of NAFLD/NASH, improved, in the development of therapeutic medical important has been a problem. However, the mechanism of development remains unclear point NAFLD/NASH in many cases, safe and highly therapeutically effective medicament NAFLD/NASH and a treatment method has not yet been established.
Lansoprazole (trade name: takepron (registered trademark) ) is, the proton pump inhibitor in the stomach wall cells (Patent Document 1) has the effect, peptic ulcer therapeutic agent commercially available as a compound having high safety. In addition, the inventors of the present invention, lansoprazole is, the first phase 1 of the first and second drug-metabolizing system (Ahr-Cyp1a1) phase 2 drug metabolism (Nrf2-HO-1) system to induce, organ oxidative stress tolerance is improved, and drug-induced acute hepatitis and the like have therapeutic effect are reported (patent document 2, non-patent document 2). However, the lansoprazole, the prevention and/or NAFLD/NASH and no report of effective in the treatment.
In addition, is NAFLD/NASH, inflammation and fibrosis by the progress of one parameter of 2, since the pathology is formed, of an agent that inhibits fibrosis which is very important. World of these agents have been made, still no report of successful development. Here, transforming growth factor - β (TGF-β) is, the fibroblasts in fibrotic disease important regulator cell activation but reports (non-patent document 3, 4), lansoprazole is, it is possible to suppress fibrosis and, involved in the expression of TGF-β has not been reported.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • WAKAYAMA MEDICAL UNIVERSITY
  • 発明者(英語)
  • YAMAMOTO, Yuta
  • UEYAMA, Takashi
  • NISHI, Toshio
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close